Success Stories

Highlights of the PCI news focused on Penn commercialization accomplishments

Four Penn Startups Make The Philadelphia Business Journal’s PHL Inno List of 2024 Startups to Watch 

Baleena, BlueWhale Bio, Treeswift and Verismo were all recognized.

PCI Recognized on’s List of Philadelphia’s Biggest Tech Moments of 2023

In the article, highlights that Penn affiliated startups attracted over $1 billion in investment capital in 2023.

ViTToria Biotherapeutics Raises Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapy Lead Candidate, VIPER-101

ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.

Heirloom Opens First Commercial Carbon Capture Plant in the U.S.

Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.

Penn spinout Interius Biotherapeutics raises another $21.5M

Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.

PCI Recognized In Clinical Leader Article about How Academic Medical Centers Can Capture Greater Value In The Cell & Gene Therapy Industry 

The Penn Center of Innovation was recognized in an article in Clinical Leader about how academic medical centers can leverage their unique advantages to develop and deliver cell and gene therapies.

Penn grads develop The Community Grocer to provide hot food for those using SNAP benefits

Penn graduates Alex Imbot ‘20 and Eli Moraru ‘21 were featured in the Inquirer for their non-profit corner store idea, The Community Grocer, which improves food access for those using SNAP benefits.

Penn is the one of the world’s best universities for VC-seeking entrepreneurs, per PitchBook data

PitchBook released its 2023 list of the best universities for founders, and Penn ranked fourth among undergraduate schools with 1,083 founders, 993 companies and $34 billion raised.

Press Highlights of FY23

During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.

Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

Penn spinout Apellis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for their drug SYFOVRE™ (pegcetacoplan injection).


Skip to content